Understand at a glance | YIDU TECH (02158) 2026 interim financial performance: a significant increase in profitability

On November 27th, YIDU TECH (02158), a leading Chinese AI healthcare company, released its mid-year financial report for the 2026 fiscal year and held a performance announcement conference. During the reporting period, the company maintained healthy growth in its business, with total revenue increasing by 8.7% year-on-year to 358 million yuan. Of particular note is the significant improvement in the company's profit quality and operational efficiency: the company's adjusted EBITDA for the existing business doubled compared to the same period last year, reaching approximately 54 million yuan, and the financial statements were close to breakeven, a year ahead of the company management's expectations. The growth momentum of the business is strong, and the core sectors saw a significant increase in new order amounts. In particular, the big data platform and solutions sector saw a 19.7% year-on-year growth in new orders, while the life science solutions sector saw a 61.1% year-on-year growth in new orders. During the conference, the management stated: "Currently, the company's large-scale model technology has entered a new stage of 'multi-point flowering and large-scale implementation.' This judgment is based on the landing of three dimensions: first, the deep application in top hospitals, with the company's AI platform landing in over 30 Grade-A hospitals and the Doctor Copilot being used nearly a thousand times per day in a single hospital; second, precise empowerment for key specialties, with a significant increase in the accuracy of TNM staging assessment by the intelligent body; and third, the smart integration of top experts, with the company using the doctors' 'digital personas' to more widely utilize the clinical experience of experts in serving patients."